Burkholderia cepacia complex: Difference between revisions
From IDWiki
Burkholderia cepacia complex
m (Aidan moved page Burkholderia cepacia to Burkholderia cepacia complex without leaving a redirect) |
mNo edit summary |
||
| Line 26: | Line 26: | ||
** [[Minocycline]] |
** [[Minocycline]] |
||
| − | {{DISPLAYTITLE:''Burkholderia cepacia''}} |
+ | {{DISPLAYTITLE:''Burkholderia cepacia'' complex}} |
[[Category:Infectious diseases]] |
[[Category:Infectious diseases]] |
||
[[Category:Gram-negative bacilli]] |
[[Category:Gram-negative bacilli]] |
||
Revision as of 12:42, 6 February 2023
Background
- Gram-negative bacillus
- Classified into nine genomovars (phenotypically similar but genotypically distinct)
- Burkholderia cenocepacia (genomovar III)
- Burkholderia multivorans (genomovar II)
- Burkholderia dolosa (genomovar VI)
- Multiple mechanisms of resistance:
- β-lactamases
- RND efflux pumps
- Altered LPS conferring polymixin resistance
- Gyrase mutations conferring fluoroquinolone resistance
Clinical Manifestations
- Opportunistic lung infections, primarily of cystic fibrosis and lung transplant patients
- Colonizes the lungs of patients with cystic fibrosis and portends a poor prognosis
Management
- Should be guided by antimicrobial susceptibility testing
- Antibiotic options include:
- TMP-SMX (preferred, if susceptible)
- Ceftazidime and ceftazidime-avibactam
- Meropenem and imipenem
- Minocycline
